Straits Times Index
3,111.65 +18.85 (+0.61%) Nikkei
26,491.97 +320.72 (+1.23%) Hang Seng
21,719.06 +445.19 (+2.09%) FTSE 100
7,208.81 +188.36 (+2.68%) BTC-USD
21,236.20 +87.62 (+0.41%) CMC Crypto 200
462.12 +8.22 (+1.81%)
Lonza Group AG (LZAGY)
| Previous close | 51.00 |
| Open | 53.65 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 53.49 - 53.99 |
| 52-week range | 49.70 - 86.31 |
| Volume | |
| Avg. volume | 98,829 |
| Market cap | 39.987B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 13.18 |
| EPS (TTM) | 4.09 |
| Earnings date | N/A |
| Forward dividend & yield | 0.30 (0.60%) |
| Ex-dividend date | 09 May 2022 |
| 1y target est | 89.00 |
- Reuters
Lonza's full-year core EBITDA up 20.7% on vaccine demand
(Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines. Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.
- Motley Fool
Should You Have Lonza Stock on Your Watchlist?
In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether investors should have Lonza on their watchlists. Keith Speights: Brian, one final topic before we get to questions.
- Investing.com
Moderna Slips As Issues At Partners Delay Overseas Release Of Shots
By Dhirendra Tripathi
